U.S. Markets closed

Adial Pharmaceuticals, Inc. (ADIL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.1700+0.0200 (+0.93%)
At close: 4:00PM EDT

Adial Pharmaceuticals, Inc.

1180 Seminole Trail
Suite 495
Charlottesville, VA 22901
United States
434 422 9800

Full Time Employees8

Key Executives

NameTitlePayExercisedYear Born
Mr. William B. Stilley III, M.B.A., MBAChairman, Pres & CEO614.1kN/A1968
Dr. Bankole A. Johnson DSc, Ph.D., M.D., M.Phil, FRCPsychFounder & Chief Medical Officer375kN/A1960
Mr. Joseph M. Truluck M.B.A., MBACFO, COO, Treasurer & Sec.225.03kN/A1978
Dr. Jack W. ReichHead of Regulatory17.01kN/A1949
Mr. Alex LugovoyChief Bus. OfficerN/AN/AN/A
Mr. Mark H. PeikinChief Strategy OfficerN/AN/AN/A
Mr. Lawrence GoldmanControllerN/AN/A1956
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in phase 3 clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Charlottesville, Virginia.

Corporate Governance

Adial Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.